Stay updated on Nivolumab in Resectable Osteosarcoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Resectable Osteosarcoma Clinical Trial page.

Latest updates to the Nivolumab in Resectable Osteosarcoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedIntroduced a consolidated Locations section listing participating states (Alabama, California, Colorado, Connecticut, Delaware, Florida, Kentucky, Maryland, New York, North Carolina, Ohio, Tennessee, Texas) and updated the page to revision v3.3.3, replacing the previous state-specific location blocks.SummaryDifference1%

- Check16 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedRevision tag updated from v3.2.0 to v3.3.2 in the page footer.SummaryDifference0.0%

- Check45 days agoChange DetectedAdded institutional names and related footer links: Moffitt Cancer Center Clinical Trials website; H. Lee Moffitt Cancer Center and Research Institute; Helpful Links Provided by. Removed a government funding status notice that previously appeared on the page.SummaryDifference0.5%

- Check59 days agoChange DetectedAdded recent update timestamps to the Study Record Dates (2025-10-31, 2025-10-30, 2025-10) and removed older August timestamps (2025-08-05, 2025-08-04, 2025-08). These changes do not alter the study content, eligibility criteria, or outcomes.SummaryDifference0.5%

- Check88 days agoChange Detected- Added a government funding notice about potential delays and current operating status, plus a link to opm.gov for updates. - Added new Genetic and Rare Diseases Information Center resource: Bone osteosarcoma. - Version revision updated from v3.1.0 to v3.2.0.SummaryDifference4%

- Check95 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Nivolumab in Resectable Osteosarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Resectable Osteosarcoma Clinical Trial page.